About
Dengue fever vaccine. Approved in Indonesia for use regardless of prior dengue exposure, in individuals aged 6 to 45 years.
What's included
Description: QDENGA is a live, attenuated, tetravalent dengue vaccine approved in Indonesia for use in individuals aged 6 to 45, regardless of prior exposure to dengue fever. It is recommended for widespread use due to the pandemic potential of dengue, with outbreaks in tropical and subtropical regions and recent occurrences in parts of mainland United States and Europe. Approximately half of the world’s population is currently at risk, with dengue fever causing an estimated 390 million infections and around 20,000 deaths worldwide each year.
Manufacturer: Takeda Pharmaceutical Company, a Japanese multinational pharmaceutical company, is the largest in Asia and among the top 15 globally.
Administration Recommendations: QDENGA should be administered subcutaneously, preferably in the shoulder. Vaccination should be postponed in individuals with a severe febrile illness. Minor infections, such as the common cold, are not a reason to delay vaccination. Anxiety-related reactions, including vasovagal responses (fainting) or stress-related responses, may occur as a psychogenic response to needle injections.
Contraindications: Hypersensitivity; individuals with congenital or acquired immunodeficiency, including those on immunosuppressive therapy such as chemotherapy or high doses of systemic corticosteroids; pregnant and breastfeeding women.
Side Effects: The vaccine is generally well tolerated. The most common reactions reported by patients include pain at the injection site (50%), headache (35%), muscle pain (31%), redness at the injection site (27%), malaise (24%), asthenia (20%), and fever (11%).
